Heart failure has devastating consequences in the United States and while the average age of patients is much higher, it can affect the lives of children and their families. For many types of pediatric heart failure patients, receiving a heart transplant is the gold standard in care. While waiting for a heart transplant, some children may require a left ventricular assist device (LVAD) to support their heart until a donor heart is available. In addition, children who are not current candidates for heart transplantation may receive an LVAD to allow the child to resume a sense of normal life.
The small, 2 inch in diameter HeartMate 3™ LVAD has been approved as a short-term therapy for adult patients with advanced heart failure since 2017 and was approved for long-term use in 2018. The HeartMate 3 was approved for use in pediatric patients in 2020, and is the latest innovation in LVAD therapy.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test